Ethynyl derivatives
US9682959B2 · kind B2 · utility
2Cited by
1References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 8, 2016 |
| Grant date | Jun 20, 2017 |
| Priority date | — |
| Expiry date | Jan 8, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D403/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to ethynyl derivatives as metabotropic glutamate receptor antagonists (negative allosteric modulators) for use in the treatment of, e.g., anxiety and pain, depression, Fragile-X syndrome, autism spectrum disorders, Parkinson's disease, and gastroesophageal reflux disease (GERD).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.